🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

Synthesis and α-Amylase Inhibition Studies of Some Coumarin Derivatives


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A series of nine molecules of coumarin hydrazone derivatives have been synthesized. The purpose of this study was to investigate the anti-diabetic activity of synthesized coumarin derivatives by inhibition of α-amylase enzyme isolated from Aspergillus niger microbial strain. The experiment was conducted by taking 5, 10, 50, and 100 μg/mL of each compound and acarbose as a positive control. The tests showed that compounds 3f (IC50 = 49.70 μg/mL), 3g (IC50 = 79.20 μg/mL), and 3i (IC50 = 48.80 μg/mL) as well as reference drug (IC50 = 81.70 μg/mL) exhibited inhibition activity against the enzyme. The synthesized compounds may be helpful in controlling the glucose level as α-amylase is one of the causes of increased sugar level in human body.

About the authors

M. Shivaprasad Shetty

Department of Chemistry, NMAM Institute of Technology

Email: nv.anil@manipal.edu
India, Nitte, Karkala, 574110

H. S. Anil Kumar

Department of Biotechnology, NMAM Institute of Technology

Email: nv.anil@manipal.edu
India, Nitte, Karkala, 574110

N. V. Anil Kumar

Department of Chemistry, Manipal Institute of Technology, Manipal Academy of higher Education

Author for correspondence.
Email: nv.anil@manipal.edu
India, Manipal, 576014

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature